After 32 years of research, Huntington’s Disease, one of the most fatal and highly progressive diseases, has been treated successfully for the first time. Doctors report that this new treatment showed a promising ability to slow the progression of the deadly disease that often leads to death within 10 to 30 years of onset for adults and 10 to 15 years of onset for teenagers.
Huntington’s disease, named after Dr. George Huntington, the American physician who provided the first definitive clinical description of the disorder, is an inherited neurodegenerative condition characterized by the progressive deterioration of nerve cells. Over time, these cells lose their ability to function and eventually die. As primary controllers of many vital bodily functions, such as movement and basic involuntary processes like breathing, nerve cells are crucial for survival. Therefore, a significant loss of nerve cells can lead to a large variety of symptoms, some of which include movement disorders, involving the inability to swallow and keep balance; mental health conditions, such as social withdrawal and bipolar disorder; and cognitive impairments.
The gene causing Huntington’s disease was identified in 1993. In the past three decades, multiple attempts to develop a therapy have failed to show optimistic clinical progression. While current patients diagnosed with Huntington’s Disease can receive medications to ease the symptoms, there is no known cure that can stop the progression of the deadly disease. What’s more, there are no scientifically proven ways to prevent the onset of the disease once one inherits the disease-inducing gene.
On September 24, 2025, however, a report from the latest clinical trial by UniQure, a biotechnology company specializing in the development of gene therapy, rekindled hope not only for patients with Huntington’s disease but also for mothers who could potentially pass on the Huntington’s gene.
In a recent press release, UniQure announced that its new treatment can dramatically reduce the progression of the symptoms by 75% over three years among those who received the gene therapy. While not a cure, the treatment shows significant improvement in patients’ quality of life. The clinical trial’s academic leader and neurologist, Sarah Tabrizi of University College London, points out that patients receiving this therapy will “be able to function longer” and “maintain their independence.”
The new treatment, the first ever to show signs of progress, focuses on directly correcting the genetic problems that cause the disease. Known as AMT-130, it is a one-time gene therapy. Unlike previous gene treatments, AMT-130 involves a brain surgery that, by directly delivering the virus to the brain, bypasses the major hurdle of the blood-brain barrier that has caused other brain-targeted drugs to fail. Guided by real-time MRI scanning, surgeons insert a modified virus into the caudate and putamen brain regions heavily affected by Huntington’s. Then, the virus, which carries a microRNA, works to reduce the production of the Huntingtin protein, thus slowing the progression of the disease.
While clinical trials of AMT-130 showed promising results, the treatment has not yet been approved for public use. Dr. Bryne, a researcher who worked closely with the UCL team that made the breakthrough, stated in an interview with BBC Radio Ulster’s Good Morning Ulster that despite the trials representing a “momentous result for the community,” they also contain “caveats.”
For one, the design of the study includes multiple limitations that could introduce bias. One notable limitation stems as a result of comparing the treated patients to an external, non-randomized control group. This method introduces a bias, as any observed differences could be caused by external differences rather than the treatment itself. Furthermore, the small sample size of 29 individuals also limits the generalizability of the findings, further skewing the biased results.
Aside from biased and limited data, uniQure also pointed out that while the therapy was “generally well-tolerated,” individuals have voiced concerns about the accuracy of this statement. Due to the wide range of possible symptoms for Huntington’s Disease, it is extremely difficult to distinguish symptoms from side effects of the treatment.
Announced in the press conference, uniQure plans to seek marketing approval in 2026. However, whether uniQure can successfully address the bias and uncertainties weighs heavily on the regulator’s decision on whether this treatment is ready and safe for public use.
Even if the treatment is approved for public use, the therapy will “not be easily accessible to all patients” as they come with price tags out of reach for many individuals. uniQure estimates that the new drug will cost similar to other gene therapies, which could exceed $3 million per patient, without factoring in the cost of brain surgery. In addition to the drug, the patient must pay for the 12-hour brain surgery. As the first potential treatment for a fatal disease and one that is highly complex, multiple sources assess that the cost itself would extinguish hope in many individuals.
Nevertheless, Huntington’s Disease researcher Dr. Byrne points out the need to “balance the optimism.” While the therapy may be out of reach for many patients, the clinical trials are still a huge milestone in research. Dr. Byrne further notes that this breakthrough “has a further impact beyond this therapy itself.” In fact, it will serve a “real positive benefit for all” future research, as the principles validated through this clinical data could be adopted by other Huntington’s Disease drug developers, speeding up drug development timelines.
Reassuring all individuals whose hopes are wavered by the worry of the therapy’s unaffordability, Dr. Byrne states, “even if someone can’t get this [treatment], there are other [drugs] coming that will be easier to get access to.” This progress in research, therefore, offers hope not just to a few but to the entire Huntington’s community.
